Mesoblast Limited American Depositary Shares MESO
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $39.00 (+125.2% upside)
Key Stats
- Today's Range
- $17.03 – $17.34
- 50-Day Range
- $13.05 – $19.36
- 52-Week Range
- $12.66 – $21.50
- Volume
- 93K shs
- Average Volume
- 201K shs
- Market Cap
- $2.25 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.10%
- Days to Cover
- 1.66
About Mesoblast Limited American Depositary Shares
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Related Stocks
Compare head-to-head: MESO vs NVDA·MESO vs AAPL·MESO vs GOOGL·MESO vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.